SVB Leerink

Selected news for the capital firm - SVB Leerink, collected since 4/2019. This capital firm shares healthcare news with Medical Research, Oncology, HealthEquity, Pfizer, AstraZeneca and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 AdaptHealth (NASDAQ:AHCO) Lowered to Hold at Zacks Investment Research com-unik.info ... walkers and hospital beds. AdaptHealth Corp., formerly known as DFB Healthcare Acquisitions Corp., is based in PLYMOUTH MEETING. “A number of other equities research analysts have also recently weighed in on the company. SVB Leerink lifted their price target on AdaptHealth from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, November 5th. TheStreet cut AdaptHealth from a “c-” rating to ...
1/12/2022 Privia Health Group, Inc. (NASDAQ:PRVA) Given Consensus Rating of “Buy” by Analysts dispatchtribunal.com ... on PRVA shares. Jefferies Financial Group started coverage on Privia Health Group in a research note on Monday, January 3rd. They issued a “buy” rating and a $33.00 price objective on the stock. SVB Leerink lifted their price target on Privia Health Group from $42.00 to $43.00 and gave the company an “outperform” rating in a research note on Wednesday, December 8th. lifted their price target on Privia ...
1/12/2022 GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Zacks Investment Research dispatchtribunal.com ... on the stock. Jefferies Financial Group initiated coverage on shares of GoodRx in a research report on Wednesday, December 1st. They issued a “buy” rating and a $47.00 price target on the stock. SVB Leerink reduced their price target on shares of GoodRx from $56.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, November 11th. Credit Suisse Group boosted their ...
1/12/2022 GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Zacks Investment Research thelincolnianonline.com ... on Thursday, November 11th. Morgan Stanley upped their target price on GoodRx from $38.00 to $41.00 and gave the company an “equal weight” rating in a research note on Friday, December 17th. Finally, SVB Leerink reduced their target price on GoodRx from $56.00 to $49.00 and set an “outperform” rating on the stock in a research note on Thursday, November 11th. Four equities research analysts have rated the ...
1/12/2022 Zogenix (NASDAQ:ZGNX) Downgraded to Sell at Zacks Investment Research - Slater Sentinel slatersentinel.com ... other equities analysts have also weighed in on the company. JMP Securities reaffirmed a buy rating and issued a $62.00 price objective on shares of Zogenix in a research note on Friday, November 5th. SVB Leerink reduced their price objective on Zogenix from $37.00 to $32.00 and set an outperform rating on the stock in a research note on Monday, December 20th. Finally, Northland Securities reduced their price objective on ...
1/12/2022 Zacks Investment Research Lowers Zogenix (NASDAQ:ZGNX) to Sell - Transcript Daily transcriptdaily.com ... Other analysts have also issued research reports about the company. JMP Securities reissued a buy rating and issued a $62.00 target price on shares of Zogenix in a research report on Friday, November 5th. SVB Leerink decreased their target price on shares of Zogenix from $37.00 to $32.00 and set an outperform rating for the company in a research note on Monday, December 20th. Finally, Northland Securities cut their price ...
1/12/2022 Amicus Therapeutics (NASDAQ:FOLD) Shares Down 16.8% on Insider Selling Daily Political ... Insiders have sold 175,536 shares of company stock worth $2,065,762 in the last 90 days. Insiders own 2.50% of the company’s stock. A number of research analysts recently weighed in on FOLD shares. SVB Leerink reduced their target price on Amicus Therapeutics from $13.00 to $12.00 and set a “market perform” rating on the stock in a report on Thursday, September 30th. JPMorgan Chase & Co. upgraded Amicus Therapeutics ...
1/12/2022 Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $159.00 etfdailynews.com ... reports about the stock. Guggenheim started coverage on shares of Beam Therapeutics in a research report on Wednesday, January 5th. They set a “buy” rating and a $130.00 price objective for the company. SVB Leerink upped their price objective on shares of Beam Therapeutics from $116.00 to $121.00 and gave the stock an “outperform” rating in a research report on Monday. Zacks Investment Research upgraded shares of Beam ...
1/12/2022 Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Rating Lowered by Zacks Investment Research etfdailynews.com ... rating in a research note on Wednesday, September 22nd. Jonestrading reissued a “buy” rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics in a report on Monday, September 13th. Finally, SVB Leerink reissued a “hold” rating and issued a $7.00 price objective on shares of Adaptimmune Therapeutics in a report on Tuesday, November 9th. One research analyst has rated the stock with a sell rating ...
1/12/2022 Illumina (NASDAQ:ILMN) Shares Gap Up Following Analyst Upgrade etfdailynews.com ... January 6th. Bank of America upgraded Illumina from an “underperform” rating to a “neutral” rating and set a $390.00 target price on the stock in a report on Friday, January 7th. Finally, SVB Leerink raised their target price on Illumina from $420.00 to $430.00 and gave the company a “market perform” rating in a report on Tuesday. One analyst has rated the stock with a sell rating ...
1/12/2022 Truist Securities Cuts Biogen (NASDAQ:BIIB) Price Target to $343.00 - Ticker Report Ticker Report ... on the stock. Barclays cut their target price on shares of Biogen from $395.00 to $290.00 and set an “equal weight” rating on the stock in a research note on Friday, October 8th. SVB Leerink dropped their price objective on shares of Biogen from $450.00 to $325.00 and set an “outperform” rating on the stock in a research note on Monday, December 20th. Truist dropped their price objective ...
1/12/2022 Amicus Therapeutics (NASDAQ:FOLD) Shares Down 16.8% After Insider Selling - Ticker Report Ticker Report ... three months, insiders have sold 175,536 shares of company stock worth $2,065,762. Company insiders own 2.50% of the company’s stock.Get Amicus Therapeutics alerts: Several equities analysts have recently commented on the stock. SVB Leerink lowered their price target on shares of Amicus Therapeutics from $13.00 to $12.00 and set a “market perform” rating on the stock in a report on Thursday, September 30th. JPMorgan Chase & Co. upgraded ...
1/12/2022 AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - The Cerbat Gem thecerbatgem.com ... the November 30th total of 7,550,000 shares. Based on an average trading volume of 4,950,000 shares, the days-to-cover ratio is presently 1.3 days.AZN has been the subject of several research reports. SVB Leerink reissued a “buy” rating on shares of AstraZeneca in a report on Sunday, December 12th. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating and set a ...
1/12/2022 Karyopharm Therapeutics (NASDAQ:KPTI) Trading 2.5% Higher on Analyst Upgrade - WKRB News wkrb13.com Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded up 2.5% during trading on Monday after SVB Leerink raised their price target on the stock from $6.00 to $8.00. SVB Leerink currently has a market perform rating on the stock. Karyopharm Therapeutics traded as high as $7.24 and last traded at $7.24. 15,119 shares were traded during mid-day trading, a decline of 99% from the average session volume of 1,630,795 ...
1/12/2022 Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Up 2.5% on Analyst Upgrade zolmax.com Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rose 2.5% on Monday after SVB Leerink raised their price target on the stock from $6.00 to $8.00. SVB Leerink currently has a market perform rating on the stock. Karyopharm Therapeutics traded as high as $7.24 and last traded at $7.24. Approximately 15,119 shares traded hands during trading, a decline of 99% from the average daily volume of 1,630,795 shares. The stock had ...
1/12/2022 Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $121.00 at SVB Leerink - Mayfield Recorder Mayfield Recorder Beam Therapeutics (NASDAQ:BEAM) had its target price increased by equities research analysts at SVB Leerink from $116.00 to $121.00 in a report issued on Monday, Price Targets.com reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s price target points to a potential upside of 59.88% from the stock’s current price.Several other research analysts also recently commented on BEAM. Guggenheim initiated coverage ...
1/12/2022 SVB Leerink Analysts Increase Earnings Estimates for Tenet Healthcare Co. (NYSE:THC) - Transcript Daily transcriptdaily.com Tenet Healthcare Co. (NYSE:THC) – SVB Leerink lifted their FY2021 earnings per share estimates for Tenet Healthcare in a report released on Thursday, January 6th. SVB Leerink analyst W. Mayo now expects that the company will post earnings of $6.51 per share for the year, up from their previous estimate of $6.36. SVB Leerink currently has a “Market Perform” rating and a $88.00 price target on the stock ...
1/12/2022 Equities Analysts Offer Predictions for REGENXBIO Inc.'s FY2026 Earnings (NASDAQ:RGNX) rivertonroll.com ... the previous year, the company posted $0.23 earnings per share.[Zacks Investment Research] downgraded REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 6th. Finally, SVB Leerink cut their price objective on REGENXBIO from $44.00 to $43.00 and set a “market perform” rating for the company in a research report on Wednesday, November 3rd. One investment analyst has rated the ...
1/12/2022 Brokers Set Expectations for REGENXBIO Inc.'s FY2026 Earnings (NASDAQ:RGNX) - Slater Sentinel slatersentinel.com ... on the company. Royal Bank of Canada upped their price target on REGENXBIO from $50.00 to $55.00 and gave the stock a “sector perform” rating in a research note on Tuesday, September 14th. SVB Leerink reduced their price target on REGENXBIO from $44.00 to $43.00 and set a “market perform” rating on the stock in a research note on Wednesday, November 3rd. Chardan Capital reduced their price target ...
1/12/2022 Computer Programs and Systems, Inc. (NASDAQ:CPSI) to Post FY2023 Earnings of $2.95 Per Share, SVB Leerink Forecasts - Transcript Daily transcriptdaily.com Computer Programs and Systems, Inc. (NASDAQ:CPSI) – Research analysts at SVB Leerink upped their FY2023 earnings per share estimates for Computer Programs and Systems in a research note issued on Thursday, January 6th. SVB Leerink analyst J. Zhang now anticipates that the company will earn $2.95 per share for the year, up from their prior estimate of $2.86.Get Computer Programs and Systems alerts: A number of other equities ...